SCN8A-Related Disorder

On this page
  1. Description
  2. Signs and Symptoms
  3. Causes
  4. Laboratory Investigations
  5. Treatment and Therapies
  6. Outlook
  7. Related Disorders
  8. Resources
  9. Research
  10. References

Summary

SCN8A-related disorder is a rare neurological condition that typically affects infants and young children. It is caused by variants (mutations) in the SCN8A gene, which affects how brain cells send electrical signals. This disorder is marked by epilepsy (seizures), challenges with thinking and learning (intellectual disability), developmental delays, problems with movement, and sometimes autism spectrum disorder. The symptoms and severity can differ greatly from child to child.

Description

SCN8A-related disorder happens when the SCN8A gene, which creates a sodium channel that helps brain cells communicate, does not work as expected. Some variants make the sodium channels overactive, while others make them underactive. These changes cause a wide range of symptoms and can lead to epilepsy and brain function differences.
Subtypes include:

  • Gain-of-function (GOF): Sodium channels are overactive, leading to epilepsy, movement disorders, and developmental delay.
  • Loss-of-function (LOF): Sodium channels are less active, leading to cognitive problems, movement disorders, and sometimes epilepsy or autism.

Severity spectrum:

  • Some children have mild symptoms, such as well-controlled epilepsy.
  • Others have severe epilepsy with developmental delays or loss of developmental skills.
  • Some affected children may die unexpectedly due to seizures (SUDEP).

Signs and Symptoms

  • Seizures often begin between birth and 18 months, with an average onset at 4-5 months, though some individuals can have seizures start later in childhood
  • Seizure types: tonic-clonic (stiffening and convulsions), absence (brief loss of awareness), myoclonic (muscle twitches), focal clonic (jerking movements of one part of the body), infantile spasms.
  • Developmental delays, including problems with motor skills and learning.
  • Some children show normal development before seizures, then lose skills (regression).
  • Movement problems: low or high muscle tone (hypotonia/hypertonia), poor coordination, dystonia, choreoathetosis.
  • Behavioral challenges, features of autism spectrum disorder.
  • Sleep disorders.

Causes

  • SCN8A-related disorder is a genetic disorder. It is not caused by anything a parent did.
  • In most cases, the genetic variant in a child’s SCN8A gene happens for the first time in the child (de novo), and it is not inherited from parents.
  • The causative SCN8A variant can be inherited from a parent with similar symptoms in a small number of cases.

Laboratory Investigations

  • Genetic testing (molecular testing for changes in the SCN8A gene) is needed to confirm diagnosis.
  • Brain imaging (MRI or CT scan) may be used to look for other causes or complications.
  • EEG (brain wave test) is used to study seizures and related brain activity; may be normal at first, but often shows abnormalities as seizures progress.
  • Tests may be repeated to monitor brain and developmental changes over time.

Treatment and Therapies

Treatment varies and depends on severity:

  • Anti-seizure medications are the main treatment but many children have seizures that are hard to control and continue despite medications (refractory).
  • Medications that block sodium channels (such as phenytoin, carbamazepine, oxcarbazepine, lacosamide, cenobamate) may help some children, especially those with gain-of-function variants. Children with loss-of-function variants may benefit from treatment with ethosuximide, valproate, or lamotrigine.
  • Other therapies: physical therapy, occupational therapy, speech therapy for movement, development, and communication problems.
  • Feeding support for children with swallowing or feeding difficulties.
  • Discuss options with your doctor to find the best treatment for your child. Side effects and treatment pros and cons should be discussed with your medical team.
  • Treatment is often long-term and may require adjustments over time.
  • Supportive care can help improve quality of life.

Outlook

  • Prognosis varies depending on symptom severity. With supportive care, some of the most severely affected children survive into adulthood.
  • Some children have ongoing seizures and developmental delays, while others may have milder symptoms.
  • Sudden unexpected death in epilepsy (SUDEP) occurs in up to 10% of cases.
  • Most children will need help in daily life and learning, with individualized education plans at school.
  • Family life will change with added needs for care, therapies, and regular doctor visits.
  • Healthy lifestyle choices, including diet and exercise, may help overall health, but there is no data on their impact on SCN8A specifically.
  • The child would likely benefit from an individualized education plan at school, and teachers should know about seizure management and learning supports needed.

Resources

The links and resources included in this section are solicited directly from the community by the Child Neurology Foundation through a formal submission process. CNF reserves the right to remove entities at any time if information is deemed inappropriate or inconsistent with the mission, vision, and values of CNF. The authors listed on this page have not endorsed the resources or links provided in this section.

International SCN8A Alliance

The International SCN8A Alliance works to accelerate advancement of therapeutics for SCN8A by fostering robust and ongoing collaboration between families, basic researchers, clinicians, organizations and industry. We support and empower those impacted by SCN8A to become engaged and effective advocates for evidence-based treatment of the full spectrum of SCN8A. Working collaboratively and promoting a global team-science approach, we work to improve the quality of life and outcomes for everyone everywhere affected by SCN8A.

Research

ClinicalTrials.gov for SCN8A (birth to 17 years)

These are clinical trials that are recruiting or will be recruiting. Updates are made daily, so you are encouraged to check back frequently.

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. This is a resource provided by the U.S. National Library of Medicine (NLM), which is an institute within the National Institutes of Health (NIH). Listing a study does not mean it has been evaluated by the U.S. Federal Government. Please read the NLM disclaimer for details.

Before participating in a study, you are encouraged to talk to your health care provider and learn about the risks and potential benefits.

For more information about participation in clinical trials, check out our education hub on the topic here.

The information in the CNF Child Neurology Disorder Directory is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. Content provided is for informational purposes only. CNF is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options.

References
  • Hammer MF, Xia M, Schreiber JM. SCN8A-Related Epilepsy and/or Neurodevelopmental Disorders. 2016 Aug 25 [updated 2023 Apr 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK379665/
  • Butler KM, da Silva C, Shafir Y, Weisfeld-Adams JD, Alexander JJ, Hegde M, Escayg A. De novo and inherited SCN8A epilepsy mutations detected by gene panel analysis. Epilepsy Res. 2017 Jan;129:17-25. doi: 10.1016/j.eplepsyres.2016.11.002.
  • Larsen J, Carvill GL, Gardella E, Kluger G, Schmiedel G, Barisic N, Depienne C, Brilstra E, Mang Y, Nielsen JE, Kirkpatrick M, Goudie D, Goldman R, Jahn JA, Jepsen B, Gill D, Docker M, Biskup S, McMahon JM, Koeleman B, Harris M, Braun K, de Kovel CG, Marini C, Specchio N, Djemie T, Weckhuysen S, Tommerup N, Troncoso M, Troncoso L, Bevot A, Wolff M, Hjalgrim H, Guerrini R, Scheffer IE, Mefford HC, Moller RS; EuroEPINOMICS RES Consortium CRP. The phenotypic spectrum of SCN8A encephalopathy. Neurology. 2015 Feb 3;84(5):480-9. doi: 10.1212/WNL.0000000000001211.
  • Meisler MH, Helman G, Hammer MF, Fureman BE, Gaillard WD, Goldin AL, Hirose S, Ishii A, Kroner BL, Lossin C, Mefford HC, Parent JM, Patel M, Schreiber J, Stewart R, Whittemore V, Wilcox K, Wagnon JL, Pearl PL, Vanderver A, Scheffer IE. SCN8A encephalopathy: Research progress and prospects. Epilepsia. 2016 Jul;57(7):1027-35. doi: 10.1111/epi.13422.
  • Wagnon JL, Barker BS, Hounshell JA, Haaxma CA, Shealy A, Moss T, Parikh S, Messer RD, Patel MK, Meisler MH. Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy. Ann Clin Transl Neurol. 2015 Dec 21;3(2):114-23. doi: 10.1002/acn3.276.
  • Perplexity AI, Inc. Perplexity [Internet]. San Francisco (CA): Perplexity AI, Inc.; 2025 [cited 2025 Oct 24]. Available from: https://www.perplexity.ai

This overview is for general information and is not a substitute for advice from your child's care team.

← Back to the Disorder Directory